Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Prestige Consumer Healthcare has a consensus “Hold” rating from six analysts, with one sell, three hold and two buy recommendations. The average 12-month price target is $70.75, compared with the stock’s opening price of $51.38.
• Recent analyst actions were mixed: Zacks Research upgraded the stock to “Hold,” Oppenheimer downgraded it to “Market Perform,” Weiss Ratings lowered it to “Sell,” and Canaccord Genuity maintained a “Buy” rating while cutting its price target to $72.
• The company exceeded quarterly expectations, reporting $0.98 in adjusted EPS versus the $0.89 consensus and revenue of $265.71 million versus $253.02 million. Revenue increased 6.5% year over year, while institutional investors own 99.95% of outstanding shares.

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) has been assigned a consensus rating of "Hold" from the six analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $70.75.

A number of research analysts have weighed in on PBH shares. Zacks Research upgraded shares of Prestige Consumer Healthcare from a "strong sell" rating to a "hold" rating in a research report on Monday, August 10th. Oppenheimer cut shares of Prestige Consumer Healthcare from an "outperform" rating to a "market perform" rating in a research note on Thursday, May 14th. Weiss Ratings downgraded shares of Prestige Consumer Healthcare from a "hold (c-)" rating to a "sell (d+)" rating in a report on Thursday, June 25th. Finally, Canaccord Genuity Group decreased their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a "buy" rating for the company in a research note on Friday, May 15th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. California State Teachers Retirement System lifted its stake in shares of Prestige Consumer Healthcare by 4,490.7% in the 2nd quarter. California State Teachers Retirement System now owns 2,630,954 shares of the company's stock valued at $124,365,000 after purchasing an additional 2,573,644 shares during the period. AXQ Capital LP acquired a new stake in shares of Prestige Consumer Healthcare during the 2nd quarter valued at about $572,000. Nykredit A S purchased a new position in shares of Prestige Consumer Healthcare in the 2nd quarter valued at about $133,000. Hsbc Holdings PLC acquired a new position in Prestige Consumer Healthcare in the 2nd quarter worth about $508,000. Finally, North Star Asset Management Inc. purchased a new stake in shares of Prestige Consumer Healthcare in the second quarter valued at approximately $9,832,000. Institutional investors and hedge funds own 99.95% of the company's stock.

Prestige Consumer Healthcare Stock Down 1.2%

Shares of NYSE:PBH opened at $51.38 on Wednesday. The company has a market cap of $2.43 billion, a price-to-earnings ratio of 14.39, a PEG ratio of 1.63 and a beta of 0.34. Prestige Consumer Healthcare has a 12 month low of $42.62 and a 12 month high of $71.07. The company has a current ratio of 3.23, a quick ratio of 1.99 and a debt-to-equity ratio of 1.06. The company has a 50-day moving average price of $49.90 and a 200 day moving average price of $54.84.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.89 by $0.09. The business had revenue of $265.71 million for the quarter, compared to the consensus estimate of $253.02 million. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The company's quarterly revenue was up 6.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, equities research analysts predict that Prestige Consumer Healthcare will post 4.56 earnings per share for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.